Literature DB >> 16636248

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

W B Pope1, A Lai, P Nghiemphu, P Mischel, T F Cloughesy.   

Abstract

Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16636248     DOI： 10.1212/01.wnl.0000208958.29600.87

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  123 in total

1.  Semi-automatic segmentation software for quantitative clinical brain glioblastoma evaluation.

Authors:  Ying Zhu; Geoffrey S Young; Zhong Xue; Raymond Y Huang; Hui You; Kian Setayesh; Hiroto Hatabu; Fei Cao; Stephen T Wong
Journal:  Acad Radiol       Date:  2012-05-15       Impact factor: 3.173

2.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

Review 3.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

4.  Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

Authors:  Peter S LaViolette; Alex D Cohen; Melissa A Prah; Scott D Rand; Jennifer Connelly; Mark G Malkin; Wade M Mueller; Kathleen M Schmainda
Journal:  Neuro Oncol       Date:  2013-02-03       Impact factor: 12.300

5.  Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Authors:  Marc C Chamberlain; Sandra Johnston
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

6.  Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

Authors:  R M Zuniga; R Torcuator; R Jain; J Anderson; T Doyle; S Ellika; L Schultz; T Mikkelsen
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

Review 7.  Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

Authors:  Joost J C Verhoeff; Olaf van Tellingen; An Claes; Lukas J A Stalpers; Myra E van Linde; Dirk J Richel; William P J Leenders; Wouter R van Furth
Journal:  BMC Cancer       Date:  2009-12-16       Impact factor: 4.430

8.  Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model.

Authors:  Csanad G Varallyay; Leslie L Muldoon; Seymur Gahramanov; Yingjen J Wu; James A Goodman; Xin Li; Martin M Pike; Edward A Neuwelt
Journal:  J Cereb Blood Flow Metab       Date:  2009-01-14       Impact factor: 6.200

9.  A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

Authors:  Camilo E Fadul; Linda S Kingman; Louise P Meyer; Bernard F Cole; Clifford J Eskey; C Harker Rhodes; David W Roberts; Herbert B Newton; J Marc Pipas
Journal:  J Neurooncol       Date:  2008-07-26       Impact factor: 4.130

10.  Time course of imaging changes of GBM during extended bevacizumab treatment.

Authors:  Suchitra Ananthnarayan; Jennie Bahng; James Roring; Phioanh Nghiemphu; Albert Lai; Timothy Cloughesy; Whitney B Pope
Journal:  J Neurooncol       Date:  2008-04-04       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.